On this page
Myotubular myopathy (X-linked)
This rare disorder primarily affects males from birth, leading to significant challenges with movement, breathing, and feeding due to impaired muscle development. Early diagnosis and supportive care are crucial for managing its complex symptoms.
Available at Jeen Health
Clinical tests that include this
Overview
X-linked myotubular myopathy (XLMTM) is a serious genetic condition that affects skeletal muscles, leading to severe weakness and reduced muscle tone from birth. The term 'myotubular' refers to an early stage of muscle development, which is disrupted in individuals with this condition [PMID:20301389]. This disorder is inherited in an X-linked recessive manner, meaning it predominantly affects males who inherit the pathogenic variant on their single X chromosome.
This condition is rare, affecting approximately 1 in 50,000 males [PMID:20301389]. It is part of a group of disorders known as congenital myopathies, meaning muscle weakness is present from birth. The severity of XLMTM can vary, but it is often severe, requiring extensive medical support [PMID:33678508].
Symptoms & clinical features
Individuals with XLMTM typically show severe hypotonia, meaning low muscle tone, and generalised muscle weakness shortly after birth. Profound weakness impacts most skeletal muscles, notably those controlling respiration, deglutition, and locomotion [PMID:33678508]. Affected infants often demonstrate markedly decreased ability to move and extremely low tone when examined.
Common signs include breathing difficulties, which may require mechanical ventilation, and significant feeding problems, sometimes necessitating a feeding tube [PMID:33678508]. Reduced foetal movement during pregnancy may also be noted. Other features can include limited facial expressions, drooping eyelids (ptosis), and certain skeletal differences such as club feet or contractures (tightening of joints). Eye movement abnormalities and long, narrow faces have also been observed.
Despite the severe physical challenges, cognitive development in individuals with XLMTM is generally not affected, though assessment can be difficult due to communication barriers.
Video: Genetics 101
Affected organs
The primary organs affected in XLMTM are the skeletal muscles throughout the body. These are the muscles responsible for voluntary movements, including walking, lifting, breathing, and swallowing. Due to the severe muscle weakness, systems relying on these muscles are significantly impacted. Respiratory muscles are particularly vulnerable, often requiring ventilatory assistance to maintain adequate breathing function.
Risks & severity
XLMTM is typically a severe condition, presenting significant health challenges often from birth. Profound weakness of the respiratory musculature creates substantial needs for breathing support, whilst difficulties with oral feeding necessitate alternative nutrition routes [PMID:33678508]. The condition manifests in the neonatal period with striking hypotonia and generalised muscle impairment.
The health outlook for males with XLMTM includes risks of respiratory compromise and difficulties with nutrition and growth. While comprehensive supportive care aims to improve outcomes, it remains a serious condition requiring ongoing medical management. Historically, many affected individuals faced life-limiting complications, though advances in respiratory and nutritional support have improved survival in some cases.
Genetic causes
X-linked myotubular myopathy is caused by pathogenic variants in MTM1. This gene encodes myotubularin, an enzyme that operates as a protein tyrosine phosphatase [PMID:20301389]. Myotubularin plays a critical role in the development and maintenance of muscle tissue, specifically in regulating how muscle cells mature and function properly.
When MTM1 contains a pathogenic variant, it leads to a myotubularin enzyme that is either non-functional or deficient. Loss of normal myotubularin activity disrupts the maturation process of muscle fibres, causing them to arrest at an immature, 'myotubular' developmental stage. This arrested development results in the characteristic severe muscle weakness and hypotonia seen in individuals with XLMTM. The myotubularin enzyme normally participates in cellular signalling pathways that govern muscle fibre architecture and membrane dynamics.
- MTM1 myotubularin 1
Inheritance pattern
X-linked myotubular myopathy follows an X-linked recessive pattern of inheritance. MTM1 resides on the X chromosome, one of the two sex chromosomes that determine biological sex.
Males possess one X and one Y chromosome. If a male inherits an X chromosome carrying a pathogenic MTM1 variant, he will develop the condition because he lacks a second X chromosome to compensate. Females possess two X chromosomes. When a female inherits one X chromosome with a pathogenic MTM1 variant, she is typically a carrier and usually does not show severe symptoms because her other normal X chromosome can compensate through a process called X-inactivation. However, some female carriers can experience milder symptoms, such as muscle weakness or cramps, due to skewed X-inactivation patterns. For each pregnancy, a female carrier has a 50% chance of passing the pathogenic variant to her children. Sons who inherit the variant will be affected, while daughters who inherit it will be carriers.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of XLMTM is often suspected based on the clinical presentation of severe hypotonia and muscle weakness at birth. This suspicion is then confirmed through genetic testing, which identifies pathogenic variants in MTM1. Genetic testing can be performed using various methods, including targeted gene sequencing or larger gene panel tests that examine multiple myopathy-related genes simultaneously.
In the UK, referrals for genetic testing are typically made by paediatricians or clinical geneticists, especially when an X-linked congenital myopathy is suspected. The NHS Genomic Medicine Service offers genomic testing, and the relevant R-code for inherited myopathy, including MTM1-related conditions, would be used for testing applications. While muscle biopsy was historically used to aid diagnosis, showing characteristic myotubular features with centrally placed nuclei in muscle fibres, genetic testing is now the primary confirmatory method and can often avoid the need for invasive biopsy procedures.
Management & lifestyle
Management of XLMTM is primarily supportive and aims to address the significant symptoms, improve quality of life, and prolong survival. This often involves a multidisciplinary team approach including paediatricians, respiratory specialists, neurologists, gastroenterologists, physiotherapists, and occupational therapists [PMID:33678508].
Key aspects of management include respiratory support, which may involve mechanical ventilation (both invasive via tracheostomy and non-invasive methods). Nutritional support is also crucial, with many individuals requiring feeding tubes such as gastrostomy to ensure adequate caloric intake and growth. Physiotherapy helps to maintain range of motion and prevent contractures. Regular monitoring for complications such as scoliosis, chest infections, and aspiration is essential, with proactive interventions implemented as needed. Genetic counsellors provide support to families, explaining the inheritance pattern and discussing reproductive options including prenatal diagnosis and preimplantation genetic testing. Emerging therapies, including gene therapy approaches, are under investigation in clinical trials.
UK care pathway
In the UK, individuals suspected of having X-linked myotubular myopathy would typically be referred to a clinical geneticist or a specialist paediatric neurology service. These services are part of the NHS Genomic Medicine Service, which coordinates access to genomic testing. Genetic counsellors play a vital role in providing information and support to families, discussing the implications of the diagnosis and inheritance patterns, and exploring reproductive options for future pregnancies. The specific genomic test for MTM1 would fall under an NHS National Genomic Test Directory R-code for inherited myopathy, facilitating access to accurate diagnosis. Following diagnosis, ongoing care is coordinated through specialist neuromuscular clinics that provide multidisciplinary input.
Frequently asked questions
What is the life expectancy for someone with X-linked myotubular myopathy?
Historically, X-linked myotubular myopathy was associated with very low life expectancy. However, with advances in medical care, particularly in respiratory and nutritional support, individuals can survive longer, often into childhood and sometimes beyond [PMID:33678508]. The severity of the condition and the level of supportive care available greatly influence individual outcomes.
Can females be affected by X-linked myotubular myopathy?
Females are typically carriers of X-linked myotubular myopathy and usually do not experience severe symptoms due to having a second functional X chromosome. However, some female carriers can show milder symptoms such as muscle weakness, fatigue, or muscle cramps, a phenomenon known as manifesting carriers. This occurs when X-inactivation is skewed, favouring the chromosome carrying the pathogenic variant.
Is there a cure for X-linked myotubular myopathy?
Currently, there is no cure for X-linked myotubular myopathy, and management focuses on supportive care to alleviate symptoms and improve quality of life. However, research into potential new treatments, including gene therapy approaches that aim to deliver a functional copy of MTM1, is ongoing and shows promising results in early studies.
How is X-linked myotubular myopathy diagnosed?
Diagnosis of X-linked myotubular myopathy is primarily made through genetic testing, which identifies pathogenic variants in MTM1. This is typically prompted by characteristic clinical features observed at birth, such as severe muscle weakness and low muscle tone, and often follows a referral from a paediatrician or clinical geneticist. Genetic testing has largely replaced muscle biopsy as the primary diagnostic tool.
What kind of support is available for families affected by XLMTM?
Families affected by XLMTM can access a range of support services in the UK, including genetic counselling, specialist paediatric care, physiotherapy, occupational therapy, and speech and language therapy. Patient organisations and charities also offer invaluable emotional support, resources, and advocacy for families living with rare conditions. Multidisciplinary neuromuscular clinics provide coordinated care and access to clinical trials where available.
References
- Woods M, Fisher G, Johnson S. A systematic review on motor outcome measures in congenital myopathy. Neuromuscular disorders : NMD. 2025. PMID: 40450412